Alnylam Pharmaceuticals
ALNY
#632
Rank
A$51.00 B
Marketcap
$393.99
Share price
2.59%
Change (1 day)
71.19%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.06

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$6.50. In 2022 the company made an earnings per share (EPS) of -$14.69 a decrease over its 2021 EPS that were of -$11.38.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.06-58.76%
2022-$14.6929.03%
2021-$11.38-3.36%
2020-$11.78-8.48%
2019-$12.877.67%
2018-$11.9539.74%
2017-$8.5512.94%
2016-$7.5738.84%
2015-$5.45-32.88%
2014-$8.13259.44%
2013-$2.26-31.25%
2012-$3.2952.94%
2011-$2.1530.77%
2010-$1.64-8.77%
2009-$1.8078.13%
2008-$1.01-70.78%
2007-$3.4699.09%
2006-$1.74-43.88%
2005-$3.10-82.33%
2004-$17.54-59.23%
2003-$43.01

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.69-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$59.06-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$12.38 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.43-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.67-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.91-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.03-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.16-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel